| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.23 | 5e-06 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.2 | 1e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.27 | 2e-05 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.23 | 0.0002 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.18 | 0.0003 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.21 | 0.0003 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0007 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.2 | 0.0009 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |